The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response ...
The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...
Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.
Zacks Investment Research on MSN6d
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United StatesSanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first ...
Fierce Healthcare says the incident — in which patient data was reportedly stolen from servers sometime after Jan. 22 — has not yet been announced by Oracle Health but was reported Friday in an ...
The FDA has approved fitusiran, now Qfitlia, as a treatment for hemophilia A or B patients, ages 12 and older, with or ...
The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ:SNY) Qfitlia (fitusiran), the first antithrombin ...
Pharmaceutical Technology on MSN7d
Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patientsDespite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper hand.
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare bleeding disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback